KeithFlahertyMD

Professor, Medicine, Harvard Medical School Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital

Dr. Flaherty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Fruit St
Lawrence House 202
Boston, MA 02114
Phone+1 617-643-5817

Fax+1 617-724-3166

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2002
Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
Johns Hopkins University School of MedicineClass of 1997

PubMed

624 citations
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, John P Ray, Carl G de Boer
Cell. 2018-11-01
525 citations
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone
Nature Medicine. 2019-12-01
615 citations
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney, Michal Barzily-Rokni
Nature Communications. 2017-10-26

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow Melanoma
Keith T Flaherty, Jennifer A Wargo, Wiley
Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age
Keith Flaherty, MD, Annals of Internal Medicine
Join now to see all

Lectures

Tissue Agnostic Drug Development Operational and Scientific Challenges. Tissue Agnostic Drug Development
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Lifesaving Protein Kills Cancer Cells and Boosts the Body’s ImmunitySeptember 18th, 2024
Scientists Discover Protein That Eradicates Cancer and Boosts the Body’s ImmunityAugust 15th, 2024
AACR Names Fellows of the AACR Academy Class of 2023April 7th, 2023
Join now to see all